Dendreon's President and CSO, Dr. David Urdal, Presents Keynote at Cancer Vaccines Conference.Business Editors/Health/Medical Writers BIOWIRE2K SEATTLE--(BUSINESS WIRE)--July 24, 2003 Presentation highlights industry leading work in development of prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. immunotherapy Dendreon Corporation (Nasdaq:DNDN) today announced that David Urdal, Ph.D., the company's President and Chief Scientific Officer, is scheduled to present a keynote address keynote address n. An opening address, as at a political convention, that outlines the issues to be considered. Also called keynote speech. Noun 1. "Prostate Cancer Vaccine Development" at the Commercializing Therapeutic Cancer Vaccines Cancer vaccines A treatment that uses the patient's immune system to attack cancer cells. Mentioned in: Pancreatic Cancer, Exocrine Conference taking place July 24 -- 25, 2003 at the Hyatt Regency Hotel The Regency Hotel was a hotel in Denver, Colorado. Built in the 1960s to serve as a regional convention center, it was famous locally for its large gold dome and the luxury of the rooms within. , Washington, D.C. "We are entering a new and exciting era in the treatment of cancer," said Dr. Urdal. "Innovative therapies based on the application of the body's own immunological defense mechanisms are now becoming a reality and hold the potential for safer and more effective treatments. Dendreon's lead immunotherapy, Provenge(R), may become one of the first approved therapeutic vaccines providing a new treatment option to androgen androgen (ăn`drəjən): see testosterone. androgen Any of a group of hormones that mainly influence the development of the male reproductive system. independent prostate cancer patients who currently have no other forms of therapy available." Dr. Urdal's presentation, scheduled for 8:15 a.m. Eastern Time, July 25, will highlight the industry leading work undertaken by scientists at Dendreon in developing the company's lead product candidate, Provenge, for the treatment of prostate cancer. Dr Urdal will discuss Dendreon's promising clinical data on Provenge, the infrastructure that Dendreon has created to effectively deliver this product candidate to patients and the agreement that it has entered into with the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. that its ongoing Phase 3 study, D9902B, may serve as the basis for the filing of a biologics license application. Provenge is currently in a pivotal Phase 3 trial, D9902B, for men with androgen independent prostate cancer. Results of a completed Phase 3 trial of Provenge, D9901, demonstrated significant clinical benefit in delaying time to disease progression and the onset of disease-related pain in patients with a Gleason score Gleason score Oncology A value derived from the Gleason grading system which is the sum of the 2 most predominant histologic patterns seen in prostate CA of 7 or less. "Therapeutic cancer vaccines are an exciting innovation in immunotherapy that promise to become a new class of marketed therapeutics with potential to target large markets and patients with unmet medical needs," said Johanna P. Morse of the Center for Business Intelligence (CBI CBI abbr. cumulative book index CBI Confederation of British Industry CBI n abbr (= Confederation of British Industry) → C.E.O.E. ), which is hosting the Commercializing Therapeutic Cancer Vaccines Conference. The CBI annual conference features the latest strategies for designing immunotherapeutic based cancer treatments and offers insights in cancer vaccine The term cancer vaccine is often used to describe a process whereby a person's immune system is coaxed into recognizing and destroying malignant cells without harming normal cells. research. About Provenge Provenge is an investigational immunotherapy for prostate cancer designed to stimulate a person's own immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. against prostate cancer. It is developed through Dendreon's proprietary Antigen Delivery Cassette(TM) technology, which utilizes a recombinant form of an antigen found in prostate cancer, prostatic acid phosphatase Prostatic acid phosphatase (PAP) is an enzyme produced by the prostate. It may be found in increased amounts in men who have prostate cancer or other diseases. This is also the same enzyme that is found in significant amounts in female ejaculate. (PAP). A double blind, placebo controlled Phase 3 trial of Provenge is underway at medical centers throughout the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . For information on participating in the Provenge trial, please call 1-87-PROVENGE (1-877-768-3643). Information on Dendreon's clinical trials is also available at www.dendreon.com. About Dendreon Corporation Dendreon is a biotechnology company developing targeted therapies for cancer. The company's lead investigational product candidate, Provenge(R), is a cancer immunotherapy undergoing a pivotal Phase 3 clinical trial phase 3 clinical trial Phase 3 study. See Phase study. for the potential treatment of androgen independent prostate cancer. In addition to its immunotherapies in clinical and preclinical development for a variety of cancers, Dendreon's product pipeline also includes monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing and small molecule product candidates. Dendreon has established important research and development alliances with industry leaders Genentech, Inc. and Kirin Brewery Co., Ltd. For more information about the company and its programs, visit www.dendreon.com. Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties surrounding the efficacy of Provenge to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such a difference include risks related to Dendreon's limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of a clinical trial for Provenge will not support an application for a biologics license, the risk that the FDA will not be satisfied with the data we provide for Provenge or approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for Provenge or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials for Provenge, the failure by Dendreon to secure and maintain relationships with collaborators, dependence on the efforts of third parties, and dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations, are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion